Pozelimab and Cemdisiran Combination Treatment in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Have Received Pozelimab Monotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 29, 2021

Primary Completion Date

October 25, 2022

Study Completion Date

October 18, 2023

Conditions
Paroxysmal Nocturnal Hemoglobinuria
Interventions
DRUG

Pozelimab

Administered Sub-cutaneous (SC) per protocol

DRUG

Cemdisiran

Administered SC per protocol

Trial Locations (13)

333

Chang Gung Memorial Hospital, Taoyuan

1907

D l Pesti Centrumk rh z Orsz gos Hematol giai s Infektol giai Int zet, Budapest

3722

Yonsei University College of Medicine, Severance Hospital, Seoul

7985

Ewha Womans University Medical Centre, Seoul

10002

National Taiwan University Hospital, Taipei

20400

Hospital Sultanah Nur Zahirah, Kuala Terengganu

49241

Pusan National University Hospital, Busan

96000

Hospital Sibu, Sibu

98000

Hospital Miri, Miri

550540

Prince of Wales Hospital, Hong Kong

06351

Samsung Medical Center, Seoul

03080

Seoul National University Hospital, Seoul

LS97TF

St. James's University Hospital, Leeds

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY

NCT04811716 - Pozelimab and Cemdisiran Combination Treatment in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Have Received Pozelimab Monotherapy | Biotech Hunter | Biotech Hunter